MA38709A1 - Compositions et procédés pour une utilisation en diagnostic médical - Google Patents

Compositions et procédés pour une utilisation en diagnostic médical

Info

Publication number
MA38709A1
MA38709A1 MA38709A MA38709A MA38709A1 MA 38709 A1 MA38709 A1 MA 38709A1 MA 38709 A MA38709 A MA 38709A MA 38709 A MA38709 A MA 38709A MA 38709 A1 MA38709 A1 MA 38709A1
Authority
MA
Morocco
Prior art keywords
nanoparticles
nanoparticle
aggregates
compositions
methods
Prior art date
Application number
MA38709A
Other languages
English (en)
Inventor
Agnès Pottier
Laurent Levy
Matthieu Germain
Laurence Poul
Céline Berjaud
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA38709A1 publication Critical patent/MA38709A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0457—Semi-solid forms, ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne des compositions et des procédés pour une utilisation en diagnostic médical et en suivi de patient. Elle concerne plus particulièrement un gel biocompatible comprenant des nanoparticules et/ou des agrégats de nanoparticules, i) la nanoparticule et/ou l'agrégat de nanoparticules comprenant un matériau inorganique comprenant au moins un élément métallique présentant un nombre atomique z d'au moins 25, chacun parmi ladite nanoparticule et/ou ledit agrégat de nanoparticules étant recouvert d'un revêtement biocompatible ; ii) la concentration en nanoparticules et/ou en agrégats de nanoparticules étant d'environ ou inférieure à 0,5 % (p/p) ; et iii) la viscosité apparente à 2s-1 du gel comprenant des nanoparticules et/ou des agrégats de nanoparticules étant située entre environ 0,1 pa.S et environ 1000 pa.S lorsqu'elle est mesurée entre 20°c et 37°c. La composition de l'invention permet généralement la délimitation et la visualisation d'au moins 40 % du tissu biologique cible lorsque ledit tissu est observé à l'aide d'un équipement d'imagerie par rayons x.
MA38709A 2013-06-20 2014-06-19 Compositions et procédés pour une utilisation en diagnostic médical MA38709A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305831 2013-06-20
PCT/EP2014/062947 WO2014202723A1 (fr) 2013-06-20 2014-06-19 Compositions et procédés pour une utilisation en diagnostic médical

Publications (1)

Publication Number Publication Date
MA38709A1 true MA38709A1 (fr) 2018-05-31

Family

ID=48745869

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38709A MA38709A1 (fr) 2013-06-20 2014-06-19 Compositions et procédés pour une utilisation en diagnostic médical

Country Status (14)

Country Link
US (1) US10588987B2 (fr)
EP (1) EP3010495B1 (fr)
JP (1) JP6560665B2 (fr)
KR (1) KR20160027009A (fr)
CN (1) CN105431141A (fr)
AU (1) AU2014283217A1 (fr)
BR (1) BR112015031977A2 (fr)
CA (1) CA2915430A1 (fr)
EA (1) EA201690050A1 (fr)
HK (1) HK1222562A1 (fr)
MA (1) MA38709A1 (fr)
MX (1) MX2015017774A (fr)
SG (1) SG11201510021TA (fr)
WO (1) WO2014202723A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6042450B2 (ja) 2011-12-16 2016-12-14 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
US11096962B2 (en) 2015-05-28 2021-08-24 Nanobiotix Nanoparticles for use as a therapeutic vaccine
CN105097174B (zh) * 2015-08-12 2018-06-22 华南理工大学 一种木聚糖季铵盐纳米磁性颗粒及其制备方法
MX2019007614A (es) 2016-12-21 2019-09-04 Nanobiotix Nanoparticulas para su uso para tratar un trastorno neuronal.
WO2018114988A1 (fr) 2016-12-21 2018-06-28 Nanobiotix Nanoparticules destinées à être utilisées pour améliorer les performances cérébrales ou pour traiter le stress
KR101949347B1 (ko) * 2017-05-24 2019-02-18 이화여자대학교 산학협력단 유방암의 재발 예측을 위한 정보제공방법
US11116793B2 (en) * 2017-11-13 2021-09-14 National University Corporation Hokkaido University Modified metal nanoparticle comprising cyclic polyether and pharmaceutical composition
CN107998395A (zh) * 2017-12-14 2018-05-08 天津市赛宁生物工程技术有限公司 一种双功能乳腺靶标及制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6161034A (en) 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US20050084869A1 (en) * 2003-10-20 2005-04-21 Sung Hyun Kim Novel composition and methods for the diagnosis of lung cancer
FR2869803B1 (fr) * 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
DE102006041495A1 (de) 2006-08-29 2008-03-20 Friedrich-Schiller-Universität Jena Substanzgemisch zur lokalen Deposition von Magnetpartikeln in einem Medium, insbesondere in tumorbefallenem organischem Gewebe, sowie Applikationskit zur Verabreichung
DE102008008522A1 (de) * 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
EP2130553A1 (fr) 2008-06-05 2009-12-09 Nanobiotix Nanoparticules inorganiques de haute densité pour détruire des cellules in-vivo
EP2275137A1 (fr) * 2009-07-10 2011-01-19 Nanobiotix Nanoparticules métalliques, leur préparation et utilisations
EP2512540B1 (fr) 2009-12-15 2019-08-07 Incept, LLC Implants et marqueurs de référence biodégradables
WO2013076305A1 (fr) 2011-11-25 2013-05-30 Danmarks Tekniske Universitet Formulation de nanoparticules solides dans un système gélifiant
JP6042450B2 (ja) * 2011-12-16 2016-12-14 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
WO2014121224A2 (fr) * 2013-02-01 2014-08-07 The Trustees Of Dartmouth College Gel à base de nanoparticules biodégradables d'oxyde de fer pour traitement d'un lit tumoral
WO2014202738A1 (fr) * 2013-06-20 2014-12-24 Nanobiotix Compositions et procédés destinés a être utilisés en oncologie

Also Published As

Publication number Publication date
BR112015031977A2 (pt) 2017-07-25
CN105431141A (zh) 2016-03-23
MX2015017774A (es) 2016-03-31
EP3010495A1 (fr) 2016-04-27
KR20160027009A (ko) 2016-03-09
JP6560665B2 (ja) 2019-08-14
US10588987B2 (en) 2020-03-17
JP2016527204A (ja) 2016-09-08
HK1222562A1 (zh) 2017-07-07
CA2915430A1 (fr) 2014-12-24
EP3010495B1 (fr) 2021-06-16
AU2014283217A1 (en) 2015-12-24
SG11201510021TA (en) 2016-01-28
EA201690050A1 (ru) 2016-05-31
WO2014202723A1 (fr) 2014-12-24
US20160136303A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
MA38709A1 (fr) Compositions et procédés pour une utilisation en diagnostic médical
Huang et al. Micro-CT and nano-CT analysis of filling quality of three different endodontic sealers
Diem et al. The effect of a nano-filled resin coating on the 3-year clinical performance of a conventional high-viscosity glass-ionomer cement
Unemori et al. Composite resin restoration and postoperative sensitivity: clinical follow-up in an undergraduate program
Montis et al. Interaction of nanoparticles with lipid membranes: a multiscale perspective
Nelson et al. Distribution and chemical speciation of exogenous micro-and nanoparticles in inflamed soft tissue adjacent to titanium and ceramic dental implants
BR112012017801A2 (pt) materiais resistentes à biopelícula
Farshad et al. Effect of imidazolium-based silver nanoparticles on root dentin roughness in comparison with three common root canal irrigants
Chisholm et al. Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD
Celik et al. Microtensile bond strength of composite-to-composite repair with different surface treatments and adhesive systems
EA201690042A1 (ru) Композиции и способы для применения в онкологии
Bakhsh et al. Nondestructive evaluation of microleakage in restored primary teeth using CP-OCT
Hashimoto et al. Nanoleakage and durability of resin/dentin bonds
Bakhsh et al. Evaluation of the adaptation of dental polymers using cross-polarization optical coherence tomography
Martins et al. Assessment of the association between overweight/obesity and traumatic dental injury among Brazilian schoolchildren
Chávez-Lozada et al. In vitro evaluation of the film thickness of self-etching resin cements
Pahwa et al. 0409 The North American Pooled Project (NAPP): Pooled analyses of case-control studies of pesticides and agricultural exposures, lymphohematopoietic cancers and sarcoma
WO2016210246A3 (fr) Mesure de concentration basée sur une image ultrasonore
Abdinian et al. Comparison of dental and skeletal indices between patients under haemodialysis and peritoneal dialysis with healthy individuals in digital panoramic radiography
CRISTIAN et al. JAW BONE ATROPHY INDUCED BY EXPOSURE TO TOXIC ENVIRONMENT USING RADIOLOGICAL INTERPRETATION.
KUMAR et al. Bifid Rib–Boon Or Bane
RU2668501C1 (ru) Способ диагностики липодистрофии
Sarkar et al. Long-term corrosion of a Ga-containing restorative material
NZ715180A (en) Compositions and methods for use in oncology
Marostegan et al. Analysis of cadmium in sodium hypochlorite solutions by Anodic Stripping Voltammetry test: a preliminary study